FDA granted an Orphan Drug Designation to Cleave Biosciences’ lead drug candidate, CB-5083, for treatment of multiple myeloma.
CB-5083 is a first-in-class, oral inhibitor of p97, an enzyme that controls various aspects of protein homeostasis.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
